ATC-324 is a potent AUTOphagy-TArgeting Chimera (AUTOTAC) degrader of androgen receptor (AR) with a DC50 of 2.05 µM. It induces autophagy–lysosomal degradation of AR, reduces nuclear AR and AR-V7 activity, and causes cytotoxicity in AR-positive prostate cancer cells, making it useful for prostate cancer research.

YJ9069 is a potent, selective and orally bioavailable PROTAC degrader of CDK12/CDK13. It inhibits proliferation in prostate cancer cells by inducing gene-length-dependent transcriptional elongation defects, leading to DNA damage, cell-cycle arrest, and significant tumor growth suppression in vivo.

YJ9069 is a potent, selective and orally bioavailable PROTAC degrader of CDK12/CDK13. It inhibits proliferation in prostate cancer cells by inducing gene-length-dependent transcriptional elongation defects, leading to DNA damage, cell-cycle arrest, and significant tumor growth suppression in vivo.

MCT-IN-1 (compound 2) is a potent and selective inhibitor of monocarboxylate transporter (MCT), with the IC50 of 9 nM and 14 nM for MCT1 and MCT4, respectively. It can be used in research as a potential target for overcoming multidrug resistance (MDR) in cancer.

Amezalpat is a first-in-class, oral, competitive antagonist of peroxisome proliferator-activated receptor α (PPARα), with IC50 of 0.04 µM. It inhibits fatty acid oxidation (FAO), disrupting cancer cell metabolism and restoring immune responses, and shows antitumor activity in research on advanced solid tumors.

YX968 is a potent, rapid, and selective PROTAC dual degrader of HDAC3/8 with DC50 values of 1.7 nM and 6.1 nM, respectively. It promotes apoptosis and kills cancer cells with a high potency in vitro and can be used in cancer research.

SHP1705 is a potent and selective activator of Cryptochrome 2 (CRY2). It inhibits BMAL1-CLOCK transcriptional activity and significantly enhances efficacy against glioblastoma stem cells (GSCs) and PDX tumors and can be used in research on GSC biology and survival in glioblastoma (GBM).

Myt1-IN-1 is a potent and selective inhibitor of membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1)(Gene: PKMYT1) with an IC50 of

Duocarmycin SA is a potent antitumor antibiotic with an IC50 of 10 pM. It is an extremely potent cytotoxic agent capable of inducing a sequence-selective alkylation of duplex DNA and can be used in research treatment for glioblastoma multiforme (GBM).

BKT-300 is a potent and selective inhibitor of Protein regulator of cytokinesis 1 (PRC1) with a Kd of 28.3 nM. It disrupts microtubule organization, inducing G2/M arrest, mitotic catastrophe, and caspase-3–dependent apoptosis, and shows promise as a research treatment for advanced acute myeloid leukemia (AML).